2020 - ESSA Pharma

Date	Title
September 21, 2020	ESSA Pharma to Participate in Oppenheimer Fall Healthcare Life Science & MedTech Summit
September 17, 2020	ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020
September 14, 2020	ESSA Pharma Announces Fast Track Designation Granted by the FDA to EPI-7386 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
September 10, 2020	ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
August 6, 2020	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2020
July 31, 2020	ESSA Pharma Completes Public Offering for Aggregate Gross Proceeds of US$48,990,000
July 28, 2020	ESSA Pharma Announces Proposed Public Offering of Common Shares
July 28, 2020	ESSA Pharma Announces Pricing of Public Offering of Common Shares
July 15, 2020	ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
June 22, 2020	ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II